Skip to content

Clinical trials

Pulmonary Disease, Chronic Obstructive trials in the United Kingdom

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Pulmonary Disease, Chronic Obstructive Country / region: United Kingdom Clear all

599 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20015
20026
200310
20046
200521
200624
200723
200823
200922
201028
201142
201235
201324
201435
201529
201638
201733
201825
201930
202021
202118
202222
202324
202416
202525
202612

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed428
Unknown status57
Recruiting39
Terminated37
Withdrawn17
Active, not recruiting15
Not yet recruiting4
Suspended1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
GlaxoSmithKline79
AstraZeneca60
Imperial College London48
Chiesi Farmaceutici S.p.A.22
Boehringer Ingelheim21
Novartis Pharmaceuticals21
Guy's and St Thomas' NHS Foundation Trust15
Royal Brompton & Harefield NHS Foundation Trust13
University of Leicester12
Pfizer9

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Pulmonary Disease, Chronic Obstructive599
Asthma70
Emphysema31
Bronchitis, Chronic23
Dyspnea16
Heart Failure16
Lung Diseases16
Lung Diseases, Interstitial12
Bronchiectasis11
Inflammation11

Trials

Showing 26 to 50 of 599. Each trial links to its page on Pharma Observatory.

499 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.